Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment - Wikidata - awgldk - TriplyDB

Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment

Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment

http://www.wikidata.org/entity/Q34407868

about

Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.

P2860

Q55098075-10595250-8D2D-403E-928A-66DDA9F1D841

P2860

Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment

http://www.wikidata.org/entity/Q34407868

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Oral glucose-stimulated serum ...... diabetes and renal impairment

@ast

Oral glucose-stimulated serum ...... diabetes and renal impairment

@en

Oral glucose-stimulated serum ...... diabetes and renal impairment

@nl

type

label

Oral glucose-stimulated serum ...... diabetes and renal impairment

@ast

Oral glucose-stimulated serum ...... diabetes and renal impairment

@en

Oral glucose-stimulated serum ...... diabetes and renal impairment

@nl

prefLabel

Oral glucose-stimulated serum ...... diabetes and renal impairment

@ast

Oral glucose-stimulated serum ...... diabetes and renal impairment

@en

Oral glucose-stimulated serum ...... diabetes and renal impairment

@nl

P1433

Q34407868-0B676BB8-2228-4A1E-A3DB-F69FE6F989DE

P1476

Q34407868-893FE1E9-EBEE-409F-A2A5-163ACB900320

P2093

Q34407868-022FE446-DD39-448A-A293-120CEC7832B4

Q34407868-2C42973F-E705-49C6-AFF2-03FACBC124FE

Q34407868-4D13D0D8-D924-4A8F-8D87-03C3BF960CA6

Q34407868-5E6DEEEC-3894-4D71-990D-C57EA17815AD

Q34407868-5EE8843F-79EC-46A3-A8A2-7199B0585A7D

Q34407868-D4D19794-0716-4C0E-B77A-7E4C26716394

Q34407868-D56092CA-172A-4C8D-BC6C-6DD385ADA22F

Q34407868-DD5333A7-6A81-4558-B181-1CC1DC7FED65

Q34407868-E508BC0C-1577-4D7B-82AA-4BD203096A1F

Q34407868-F2C6932E-371A-495A-8FBD-5C6985F9B094

P2860

Q34407868-19A97F9B-1C4F-40B6-99ED-824A9DE6BB5C

Q34407868-1CEACF1D-6D46-4933-B7FB-A378CE8845DB

Q34407868-3F8084B0-818E-4418-8A36-CFC391C68DF3

Q34407868-50200D3B-CED1-4D3B-AE34-ED681199B9A1

Q34407868-54DC101A-6A2D-4AD7-B5A2-A2DE9B3B0B4C

Q34407868-59E2BF9D-58A8-47E0-B98D-37A66EFA35D0

Q34407868-63B8097A-A693-4146-B811-688FCE9E3CAE

Q34407868-6979E7D0-70EA-4AE9-8249-C3C9DDE9E798

Q34407868-6FF490C9-9586-4132-817C-335C79395BBF

Q34407868-7660EC41-0E1A-4657-A89F-D95B556FE8A1

P304

Q34407868-F6653AC0-37C4-4599-8A26-BFA433CE0E37

P31

Q34407868-22CC3D82-7D18-48DC-8397-1BE3B125DAEE

P356

Q34407868-1B7F96D3-5021-46F2-81F0-8A27FCE1D5EB

P433

Q34407868-D3B4AB48-1A00-4305-88B3-915D6762E736

P478

Q34407868-39C17B86-B92F-4932-81FF-090B31AC9BFC

P577

Q34407868-637574C8-CE88-4320-930D-F83201E93534

P5875

Q34407868-4EFC7B60-FC41-4253-9275-7B54228EA6F0

P698

Q34407868-E7583A74-F9CC-4D60-8A70-7595133B230A

P932

Q34407868-1B5C17F6-30A8-48CB-B60A-ADB6D1ED5A44

P356

P1433

Journal of Diabetes Investigation

P1476

Oral glucose-stimulated serum ...... diabetes and renal impairment

@en

P2093

Atsunori Kashiwagi

http://www.w3.org/2001/XMLSchema#string

Hiroshi Maegawa

http://www.w3.org/2001/XMLSchema#string

Hisazumi Araki

http://www.w3.org/2001/XMLSchema#string

Keiji Isshiki

http://www.w3.org/2001/XMLSchema#string

Shin-Ichi Araki

http://www.w3.org/2001/XMLSchema#string

Shinji Kume

http://www.w3.org/2001/XMLSchema#string

Syohei Yoshida

http://www.w3.org/2001/XMLSchema#string

Takashi Uzu

http://www.w3.org/2001/XMLSchema#string

Yoshikata Morita

http://www.w3.org/2001/XMLSchema#string

Yuki Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Decreased insulin requirement in acute renal failure in diabetic nephropathy

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

P304

435-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDI.12169

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259552726

http://www.w3.org/2001/XMLSchema#string

P698

25411603

http://www.w3.org/2001/XMLSchema#string

P932

4210066

http://www.w3.org/2001/XMLSchema#string